Solid tumours and malignant haemopathies
The tests carried out in the Cellular Haematology, Cytogenetics and Molecular Genetics departments of Eurofins Biomnis enable the optimum management of cancer patients (malignant haemopathies or solid tumours).
We offer a complete range of analytical tests allowing the diagnostic, prognostic and theranostic evaluation of all malignant haemopathies (chronic lymphoproliferative syndromes, myelomas, chronic myeloproliferative neoplasias, myelodysplastic syndromes, acute leukaemias, etc.) and a wide spectrum of solid tumours (breast, lung, colorectal & gastric cancers, melanomas, sarcomas, etc.).
The various departments employ state-of-the-art technology (10-colour flow cytometers, automatic metaphase finders, sequencing platforms…) operated by technicians specialised in clinical pathology.
Our physicians, pharmacists and clinical pathologists are members of the following societies: GFHC (French Cellular Haematology Group), SFH (French Haematology Society), AFC (French Cytometry Association), GFCH (Francophone Group for Cytogenetic Haematology), ACLF (Francophone Cytogeneticists Association), GFCO (French Group for Study of Cytogenetics in Oncology) and GBMHM (Molecular Biology Group for Haematological Malignancies).
The Cellular Haematology/Cytogenetics Department is fully accredited for all the analyses it performs, in accordance with the NF EN ISO 15189 standard.
Experts
Contact by email
Contact by email
Contact by email
Contact by email
Cellular haematology
A cytological examination is often the initial diagnostic test performed in the case of malignant haemopathies, along with a complete blood count.
This analysis can provide or confirm a diagnosis and help determine the follow-up tests to be performed. The cells found in blood or bone marrow are stained with May-Grünwald-Giemsa stain and, if necessary, with other stains (Perls, myeloperoxidase). The qualitative and quantitative analyses of these cells under the microscope are performed by a specialised cytologist.
Cytology also plays a role in the non-malignant context (e.g. drepanocytosis, screening for schizocytes, lysosomal storage disease, etc.)
Immunophenotyping by flow cytometry is used to investigate the antigens expressed by cells found in the blood or bone marrow. The expression profile thus obtained makes it possible to characterise the cells as normal or pathological, mature or immature (blasts), B or T lymphoids, etc.
This examination complements the myelogram in the diagnosis of acute leukaemia and myeloma, and facilitates the differential diagnosis of monocytosis. It is essential for the classification of chronic lymphoproliferative syndromes: LLC (calculation of the Matutes score, prognostic marker CD38), follicular lymphoma, hairy cell leukaemia, mantle cell lymphoma, etc.
Required documents for Cellular haematology
B8-INTGB – Malignant Blood Disorders request form.
Experts
Contact by email
Contact by email
Acquired cytogenetics
Acquired or onco-haematological cytogenetics is a discipline that applies two techniques: conventional cytogenetics (performance of a karyotype and search for abnormalities in number or structure) and molecular cytogenetics (Fluorescence in Situ Hybridisation or FISH) with targeted fluorescent probe).
In the context of malignant haemopathies, the combination of karyotype and haematological FISH can facilitate diagnosis (e.g. translocation t(9;22) (q34;q11) signalling CML), prognosis (e.g. EVI1 rearrangement in MDS, t(4;14) (p16;q32) translocation in myelomas), and also guide therapeutic management (e.g. TP53 deletion in CLL: resistance factor to fludarabine).
In the context of solid tumours, the FISH technique is essential to specify a histological diagnosis (e.g. EWS rearrangement in Ewing’s sarcoma) and / or guide therapeutic management (e.g. HER2 amplification in invasive breast cancer, ALK or ROS1 rearrangement in non-small cell lung cancer).
At Eurofins Biomnis, we offer a complete panel of FISH probes for the investigation of malignant haemopathies and solid tumours.
The collaboration between clinical pathologists specialised in cytology, immunophenotyping, and anatomical pathologists is crucial for the processing of samples and an optimal interpretation of the results.
Required documents for Acquired cytogenetics
B8-INTGB – Malignant Blood Disorders request form.
B9-INTGB – Oncology-Solid tumors request form.
Experts
Contact by email
Contact by email
Contact by email
Somatic genetics
Acquired genetics, also referred to as somatic or onco-haematological genetics, is a discipline which requires a broad spectrum of specialised and innovative techniques.
Rapid technological developments in the field of genetics are leading to increasingly personalised care for patients with cancer.
The development of innovative molecular techniques, in particular high-throughput sequencing, now allows the simultaneous analysis of several dozen genes whose alterations have a major impact in onco-haematology. As a result, targeted panels are now available for the diagnostic, prognostic or theranostic management of myeloid haemopathies: myeloproliferative neoplasias (NMP), myelodysplastic syndromes (MDS), myelomonocytic leukaemia (LMMC) and acute myeloid leukaemia (AML).
We also offer several tests dedicated to chronic myelogenous leukaemia (CML) covering the entire natural progression of the disease: identification of the fusion transcript, monitoring of residual disease, search for mutations resistant to TKIs.
For the therapeutic management of certain solid tumours, cytogenetic (FISH) and molecular biology techniques are indispensable – therefore, the term “companion test” for targeted therapy is commonly used. For the past ten years, these molecular tests have been offered at Eurofins Biomnis in an isolated test format (e.g. EGFR, KRAS, NRAS or BRAF).
The laboratory now offers various gene panels dedicated to each organ (e.g. lung, colon, etc.) and analysed by high-throughput sequencing (NGS). This technique allows the molecular characterisation of tumours by simultaneously analysing several genes (from 3 to 24) involved in carcinogenesis.
Required documents for Somatic genetics
B8-INTGB – Malignant Blood Disorders request form
B9-INTGB – Oncology-Solid tumors request form
Resources
Cellular haematology
Focus 43 – Immunophenotyping
Focus 36 – Myeloma haemostasis
Focus 23 – Multiple myeloma
Focus on – Pathological diagnosis and follow up of patients with Acute leukemia
Focus on – Pathological diagnosis and follow up of patients with Mature Lymphoïd Neoplasms
Focus on – Pathological diagnosis and follow up of patients with Chronic Myeloid Neoplasms
Acquired cytogenetics
Focus 23 – Multiple myeloma
Focus on – Pathological diagnosis and follow up of patients with Acute leukemia
Focus on – Pathological diagnosis and follow up of patients with Mature Lymphoïd Neoplasms
Focus on – Pathological diagnosis and follow up of patients with Chronic Myeloid Neoplasms
Somatic genetics
Focus 55 – Prosigna® (PAM50)
Focus on – Progensa™ urine test for PCA3
Focus on – Pathological diagnosis and follow up of patients with Acute leukemia
Focus on – Pathological diagnosis and follow up of patients with Mature Lymphoïd Neoplasms
Focus on – Pathological diagnosis and follow up of patients with Chronic Myeloid Neoplasms
Panel sheet – Myeloproliferative neoplasms – Diagnosis
Panel sheet – Myeloproliferative neoplasms – Prognosis
Panel sheet – Chronic Myelomonocytic leukemia
Panel sheet – Myelodysplastic syndromes
Panel sheet – Acute myeloid leukaemia panel
Focus on – Management of solid tumours in Biopathology
Oncology sheet – Pulmonology
Oncology sheet – Digestive system
Oncology sheet – Gynaecology
Oncology sheet – Other solid tumours